Twist Bioscience Corporation (TWST)
| Market Cap | 3.63B |
| Revenue (ttm) | 391.56M |
| Net Income (ttm) | -76.58M |
| Shares Out | 61.31M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 815,034 |
| Open | 60.23 |
| Previous Close | 61.00 |
| Day's Range | 58.56 - 60.84 |
| 52-Week Range | 23.30 - 66.06 |
| Beta | 2.21 |
| Analysts | Buy |
| Price Target | 46.88 (-20.74%) |
| Earnings Date | May 4, 2026 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $46.88, which is a decrease of -20.74% from the latest price.
News
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...
Twist Bioscience Transcript: Leerink Global Healthcare Conference 2026
Strong growth driven by new product launches, automation, and AI-enabled services has expanded the addressable market and improved margins. Strategic focus on high-throughput solutions, commercial excellence, and a shift to fee-for-service contracts positions the company for continued revenue and margin expansion.
Twist Bioscience Transcript: Barclays 28th Annual Global Healthcare Conference
Resegmentation and AI integration are driving rapid growth in DNA synthesis, protein solutions, and NGS, with new products like TrueAmp and MRD Express expanding market reach. Margin expansion continues, supported by operational scale and innovation, with breakeven targeted by Q4.
Twist Bioscience Transcript: TD Cowen 46th Annual Health Care Conference
Management reaffirmed the goal of Adjusted EBITDA breakeven by Q4 FY2026, driven by margin expansion and disciplined OpEx. AI and MRD are fueling rapid growth, with automation and product innovation providing competitive advantages. Long-term, the addressable market is targeted to reach $12B+.
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement wi...
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twis...
Twist Bioscience Transcript: AGM 2026
The meeting covered board introductions, voting on three key proposals, and a Q&A session. All director nominees were elected, executive compensation was approved, and the auditor was ratified. No questions were submitted by stockholders.
These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results
Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted better-than-expected sales for the first quarter.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Why Is Twist Bioscience Stock Soaring Monday?
Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with the Wall Street expectations.
Twist Bioscience Earnings Call Transcript: Q1 2026
Q1 revenue grew 17% year-over-year to $103.7M, with gross margin rising to 52% and strong demand from AI-driven discovery. Guidance for FY26 was raised to $435M–$440M, with adjusted EBITDA break-even expected in Q4. Investments in sales and digital infrastructure support continued growth.
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Twist Bioscience Transcript: 44th Annual J.P. Morgan Healthcare Conference
Semiconductor-based DNA synthesis technology and rapid product innovation have driven strong revenue growth, margin expansion, and customer acquisition. AI-enabled drug discovery and NGS applications are key growth drivers, with break-even targeted for Q4 2026.
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quar...
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciar...
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to suppo...
Twist Bioscience Transcript: Wolfe Research Healthcare Conference 2025
Revenue and gross margin exceeded guidance despite a tough environment, with strong growth in both NGS and DNA synthesis segments. A major pharma order and new product wins are driving momentum, while a single NGS customer transition is causing short-term revenue noise. New disclosures and a focus on revenue growth are expected to support future upside.
Can Twist Bioscience Drop More?
Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but signifi...
Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses
Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.
Twist Bioscience Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue growth, with gross margin surpassing 50% and significant improvements in adjusted EBITDA loss. Fiscal 2026 guidance projects 13–15.5% revenue growth, margin expansion, and adjusted EBITDA breakeven by year-end, driven by AI and diagnostic customer ramps.
Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings
Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.
Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...